Onconetix Inc

ONCO

Company Profile

  • Business description

    Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

  • Contact

    201 East Fifth Street
    Suite 1900
    CincinnatiOH45202
    USA

    T: +1 513 620-4101

    https://www.onconetix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    5

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,830.4052.500.60%
CAC 407,878.46111.751.44%
DAX 4024,549.56342.651.42%
Dow JONES (US)44,458.30217.540.49%
FTSE 1008,867.0212.840.15%
HKSE23,923.0730.750.13%
NASDAQ20,611.34192.870.94%
Nikkei 22539,610.61210.67-0.53%
NZX 50 Index12,741.0827.53-0.22%
S&P 5006,263.2637.740.61%
S&P/ASX 2008,594.0055.400.65%
SSE Composite Index3,504.3511.300.32%

Market Movers